About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

NCT00141830·35 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Wyeth is now a wholly owned subsidiary of Pfizer

Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Clinical diagnosis of active rheumatoid arthritis for at least 6 months and on a stable dose of methotrexate for at least 12 weeks
Rheumatoid arthritis onset after 16 years of age

You may not be if

Any significant health problem other than rheumatoid arthritis
History of male or female reproductive system cancer
Clinically significant laboratory abnormalities

The record

StatusCompleted

PhasePhase 2

Taking part159

StartedAug 2005

UpdatedSep 29, 2020

Conditions

Rheumatoid Arthritis

Where35

Largo, Florida, United States
Palm Harbor, Florida, United States
Sarasota, Florida, United States

Clareo Health | Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis